The PharmaVoice 100: Trailblazers | PharmaVoice

To blaze a trail is to step away from the well-worn path and its guaranteed, predictable success — trailblazers take new roads with greater risk but the chance to lead on the cutting edge.

The biopharma industry is a hotbed of innovation and a place for thinking differently about how to solve not just the medical mysteries of today but also the ones of tomorrow. And trailblazers don’t just advance scientific understanding — they also foster breakthroughs as strategists, infrastructure experts, communicators and more.

As important decisions about drug prices and regulatory efforts drown out the highest levels of the biopharma space, these are the leaders changing the fabric of the industry from within. The trailblazing leaders on this year’s PharmaVoice 100 list have innovative mindsets that make them invaluable assets to an industry built upon that foundation.

And when we talk about the future of the life sciences, these trailblazers are also clearing paths for others to follow in their footsteps, supporting a new generation of scientists, thinkers and creators as they strive to advance the industry in new and exciting ways.

Here are the 2023 PharmaVoice 100 trailblazers shaping tomorrow’s pharma landscape.

Shiz Aoki

“I’m excited for advancements in AI to accelerate our ability to generate beautiful and scientifically accurate figures in a fraction of the time.” Read more ➔

Jessica Ballinger

“Nothing we are doing at Lyndra has been done before, from R&D to manufacturing to regulatory. We’re reinventing medicine.” Read more ➔

Kate Broderick

“We can solve so many unmet medical needs with mRNA vaccines and nucleic acid medicines that it feels like the possibilities are endless.” Read more ➔

Dr. Uli Broedl

“My favorite part of the work day is exploring novel opportunities to create value for patients.” Read more ➔

William Wei Cao

“When the macroenvironment improves, I would expect to see the next generation of cell therapies emerge with faster delivery, ease of use and lower cost.” Read more ➔

Dr. Elizabeth Garner

“I believe that both inspiration and motivation are achieved by example.” Read more ➔

Mei Mei Hu

“My favorite part of the day is my morning routine [when] I meditate by playing my singing bowls and set my intentions for the day.” Read more ➔

Hong Jin

“My favorite part of the day is getting the job done.” Read more ➔

Henry Pelish

“Research is at the core of my role in leading drug discovery and I’m fortunate to work with a talented internal team, scientific partners and a community of leading academic collaborators.” Read more ➔

Elisabet de los Pinos

“I am very excited by the promise of creating treatments for conditions we previously thought were untreatable.” Read more ➔

Dr. Shankar Ramaswamy

“The industry is moving away from aiming for incremental benefits to delivering transformational outcomes to patients.” Read more ➔

Luis Roman

“Resiliency is built when barriers are removed and decisions are made together. We change and become resilient the more we integrate.” Read more ➔

Dr. Raymond Sanchez

“Far too often, we hear people say that neuroscience R&D is a ‘graveyard of failed therapies.’ I simply refuse to believe that.” Read more ➔

Pascal Touchon

“Obtaining the first-ever approval for an allogeneic cell therapy has been a landmark achievement for the team as they are making history.” Read more ➔